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Projecting renal replacement therapy–specific end-stage renal (CORR), a population-based, nation-wide organ failure
disease prevalence using registry data. End-stage renal disease registry [1] operated by the Canadian Institute for Health
incidence and prevalence are increasing in many countries Information (CIHI). Demographic data (e.g., birth date,worldwide. Projections of ESRD prevalence are useful for fore-
gender, race, province of residence) and baseline clinicalcasting future resource requirements, and organ failure registry
data (e.g., primary renal diagnosis (PRD), predialysisdatabases are valuable for the development of appropriate
projection models. We outline one method of generating renal comorbid conditions) are collected from patients by each
replacement therapy (RRT)–specific ESRD prevalence projec- renal center upon RRT initiation. Therapeutic history
tions based on data obtained from the Canadian Organ Re- data (e.g., RRT assignments, dialytic modality switches,placement Register (CORR). To illustrate the methods, we
transplantations, graft failures) are submitted annually.present national RRT-specific prevalence projections for Can-
ada to the year 2005. Continued large increases in ESRD inci- Death data (i.e., date and cause of death) are reported
dence and prevalence are projected, particularly among diabet- along with the other follow-up information. Coverage
ics. As of December 31, 1996, there were 17,807 patients by CORR is complete in that records from all 86 Cana-
receiving RRT in Canada. This number is projected to climb
dian renal centres are submitted annually. As well, allto 32,952 by the end of 2005, for a relative increase of 85%
follow-up time is included, including the first 90 days(average relative increase of 5.8% per year). Registry data are
a useful basis for future health care planning. post-initiation of RRT.
Population data, including census counts, intercensal
estimates, and population projections, were obtainedEnd-stage renal disease (ESRD) incidence and preva-
from Statistics Canada [8].lence are increasing in Canada [1], the United States [2],
Australia [3], and several European countries [4]. The Overview of projection model
considerable public health importance of ESRD derives
Below, we provide a basic description of a model pre-from the high mortality rate and impaired quality of life
viously employed to project RRT-specific national prev-among patients, and the high cost of renal replacement
alence up to the year 2005 [6]. Since the funding of renaltherapy (RRT) [5]. Projections of future numbers of
centres is largely within the jurisdiction of the provincialpatients receiving RRT are of interest to health care
governments, projections to 2005 by province were laterplanners and providers to forecast equipment, facility,
attempted using very similar methods [7]. As an illustra-manpower and other resource requirements. We pro-
tion of the model’s application, we present national re-pose one method of projecting RRT-specific ESRD prev-
sults based on the latter study, derived by summingalence using registry data, which has been previously
across all provinces. Readers interested in more statisti-employed to generate prevalence projections for Canada
cal details of the projection model are referred to theat both the national [6] and provincial [7] levels.
former paper [6].
At the time of the most recent projections, CORR
METHODS data were available for all patients initiating RRT in
Data sources Canada between January 1, 1981 and December 31, 1996.
End-stage renal disease patient-specific data were ob- Patients were classified by age (#44, 45–64, $65), prov-
tained from the Canadian Organ Replacement Register ince, and diabetes status. Separate projections were pro-
duced by province for each age 3 diabetes cross-classifi-
cation, to allow the parameters of the model to differKey words: demography, dialysis, end-stage renal disease, epidemiol-
ogy, Markov model, Poisson, transplantation. across subpopulations defined by these variables. It was
expected a priori that incidence (i.e., new case rate per 2000 by the International Society of Nephrology
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Table 1. Markov model statesyear) and/or prevalence (i.e., year-end number of pa-
tients receiving RRT) trends in each subpopulation State RRT
would be different. 1 Hemodialysis
2 Peritoneal dialysisThe number of patients receiving RRT at any time
3 Functioning transplantbeyond the conclusion of the period of observation, De-
4 Death
cember 31, 1996, is composed of: (i) survivors of incident
cases occurring between 1995 and 2005, and (ii) survivors
among “currently prevalent” patients (i.e., patients re-
ceiving RRT as of December 31, 1996). Thus, although
(i) and (ii) are not important quantities by themselves
prior to being summed to calculate prevalence, it is im-
portant to consider the two in isolation since, as will
be discussed in the paragraphs that follow, these are
computed separately. All statistical analyses were con-
ducted using the statistical computing language SAS
(v6.12, SAS Institute; Cary, NC).
Incidence projections
Annual incidence rates between 1997 and 2005 were
estimated by extrapolating Poisson regression [9–11]
models based on the 1981–1996 data. That is, Poisson
regression models were fitted to the 1981–1996 data, and
the coefficients from these models were used to estimate
annual incidence rates for each year between 1997 and
2005. Thus, the model for each subpopulation defined
by age and diabetes status, would have the form:
Fig. 1. Therapeutic “states” for the Markov model of patient follow-
up. 1: Hemodialysis (HD), 2: peritoneal dialysis (PD), 3: functioninglog{I(y)} 5 b0 1 b1y 1 b2(y 2 1988)2 (Eq. 1)
transplant (T), 4: death (D). Arrows denote possible state transitions.
where I(y) is the incidence rate during year y. Subtracting
1988 in the quadratic term dampens the correlation be-
tween b1 and b2. Estimates of b0, b1, and b2, were used to
lent cases (i.e., those receiving RRT as of December 31,project incidence rates for future years via the following
1996), we project the follow-up experience for each ofequation:
these two groups separately. A Markov model [12, 13]
I(y) 5 exp[b0 1 b1y 1 b2(y 2 1988)2], was employed for this purpose. We first describe the
fundamental quantities of the Markov model, then de-for y 5 1997, 1998, . . . , 2005 (Eq. 2)
scribe how they are used to project patient follow-up.
Having projected the incidence rate, the annual num- A Markov model is, basically, a matrix of state transi-
ber of incident cases was obtained by multiplying the tion probabilities. In our case, we have defined four
projected rate by the projected population size. Models states, as listed in Table 1: hemodialysis (HD), peritoneal
were fitted separately by province and diabetes status, dialysis (PD), functioning transplant, and death. In the
and contained terms for age, year, and all indicated age 3 formulae to follow, the numbering of the states is consis-
year interactions. Quadratic terms in year were entered tent with that listed in Table 1. Naturally, death is an
as needed. Diabetic status-specific models permitted the “absorbing” state since transfer from it is impossible.
age and year effects to be different for diabetics and Transitions among each of the other three states are
non-diabetics, without the need for third order interac- possible, as are transitions from all RRT states to the
tion terms (e.g., age 3 year 3 diabetes), which are diffi- death state. A state transition diagram is presented in
cult to interpret. Fig. 1.
A second set of projections was made wherein it was A Markov model can be conceptualized as a general-
assumed that incidence during 1997–2005 remained con- ization of the familiar survival model. Typically in sur-
stant at the average across the 1994–96 period. vival analysis, there are 2 states: alive and dead. Since
transition is possible in only one direction, a Markov
Prevalence projections model of this setting would reduce to one quantity: sur-
Having projected the number of incident cases during vival probability. Had only the total number of patients
receiving RRT been of interest, as opposed to RRT-1997–2005, and knowing the number of currently preva-
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specific prevalence, a survival model would have sufficed. time t and state k at time t 1 6, and cj(t) is the number
of patients in state j at time t.Since the objective is RRT-specific projections, we must
To illustrate the use of these quantities, we list someestimate the fraction of patients, among incident cases
calculations. The number of patients with a functioningfor each year, that will begin treatment on HD, PD and
transplant for a given patient cohort after 12 months oftransplant. As well, we must estimate modality switching
follow-up could be computed, in terms of the RRT-probabilities.
specific patient numbers at time 6, as:
Modality assignment probabilities
n3(12) 5 n1(6)q13(6,12) 1 n2(6)q23(6,12) 1For incident cases, it is necessary to estimate the frac-
n3(6)q33(6,12) (Eq. 6)tion that will begin on each RRT. Set qj(t) 5 P(state j
at time t), for j 5 1, 2, and 3, t 5 0, 6, 12, 18, where t Note the distinction between nj(t), the number of pa-is measured in months of follow-up (i.e., months post- tients from a hypothetical cohort initiating RRT during
initiation of RRT), and where the numbering of the a given calendar year, and cj(t) the actual number ofstates is consistent with Table 1. Hence, t 5 0 corre- patients on the CORR database (i.e., summed over all
sponds to initial RRT assignment. We estimate qj(0) by: patient cohorts from 1981 to 1996, inclusive) upon which
our analysis is based.qj(0) 5 cj(0)/{c1(0) 1 c2(0) 1 c3(0)} (Eq. 3)
For notational convenience, we can write:
where cj(0) is the number of patients beginning in state
j, based on the CORR data file previously described. Of
course, q4(0) 5 0. Only 1990–1996 data were employed Q(t,t16) 5 *q11(t,t16) q12(t,t16) q13(t,t16) q14(t,t16)q21(t,t16) q22(t,t16) q23(t,t16) q24(t,t16)q31(t,t16) q32(t,t16) q33(t,t16) q34(t,t16)q41(t,t16) q42(t,t16) q43(t,t16) q44(t,t16)*to estimate modality assignment probabilities for the
1997–2005 period, since future RRT assignment patterns
are more likely to reflect those most recently experi- q(t) 5 [q1(t), q2(t), q3(t), q4(t)], andenced, and since data volume in the most recent 7 years
n(t) 5 [n1(t), n2(t), n3(t), n4(t)], (Eq. 7)was sufficient for such purposes. Consistent with the
incidence models, each quantity in the follow-up models which allows us to economically re-express quantities
is estimated separately by province, age (#44, 45–64, such as those in Eq. 6 as:
$65) and PRD (diabetic, non-diabetic). For clarity, nota-
n(t 1 6) 5 n(t)Q(t,t 1 6) (Eq. 8)tion identifying the particular subgroup have been sup-
pressed. Thus, formulae which follow were applied sepa-
We can further project a patient cohort through the
rately to each province/age/diabetes stratum.
follow-up period as follows:
Transition matrices n(t 1 24) 5 n(t)Q(t,t 1 6)Q(t 1 6,t 1 12) 3
It makes sense that state transition probabilities would
Q(t 1 12,t 1 18) 3
not be constant over follow-up time (i.e., time post-initia-
Q(t 1 18,t 1 24) (Eq. 9)tion of RRT). For example, transplants among ESRD
patients in Canada usually take place within the first
As an example, the following transition matrix is for
three years of follow-up [1]. As well, switching dialytic
Ontario non-diabetics aged 45–64, for follow-up interval
modalities is much more frequent just after beginning
12–18 months post-initiation of RRT:
on dialysis, and stabilizes thereafter. For these reasons,
transition matrices were estimated separately for each
6-month follow-up window. We represent the probability
Q(12,18) 5 *0.868 0.008 0.074 0.0490.055 0.848 0.053 0.0440.016 0 0.977 0.0080 0 0 1 * (Eq. 10)of being in state k at time t 1 6, conditional on being instate j at t months, by:
qjk(t,t 1 6) 5 Based on this matrix, for patients on HD one year
P(state k at time t 1 6 | state j at time t) (Eq. 4) post-initiation of RRT, the probability of remaining on
HD at the end of month 18 equals 86.8%, while thewhere the “|” denotes “given” or “conditional on”. We
probability of being on PD is 0.8%. The probability ofestimate these quantities by:
having a functioning transplant at month 18 is 7.4%, and
qjk(t,t 1 6) 5 cjk(t,t 1 6)/{cj1(t,t 1 6) 1 cj2(t,t 1 6) 1 that of dying is 4.9%. Neglecting round-off error, the
elements in each row sum to 1.cj3(t,t 1 6) 1 cj3(t,t 1 6)} (Eq. 5) The following therapy assignment vector pertains to
Ontario non-diabetics aged #44:where cjk(t,t 1 6) is the number of patients in state j at
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q(0) 5 [0.584, 0.372, 0.044, 0] (Eq. 11)
indicating that the probability is 58.4% that such patients
begin on HD, 37.2% for PD and 4.4% for an initial
transplant. Note that although the 4th element of q(0)
element is uninformative in that q4(0) 5 0 by definition,
it is included so that the q(0) vector will conform with
the Q matrices.
Projecting follow-up of incident cases
Now that the essential quantities of the projection
model have been calculated, we outline how they are
combined to generate prevalence projections. Denote
the number of incident cases during year y, for a particu-
lar province/age/diabetes stratum by Iy, the product of
the incidence rate and population size. If we can assume
that ESRD incidence occurs uniformly across each calen-
dar year, then, on average, cases will occur at the mid-
point: 30/06/y. The distribution by modality of such inci-
dent cases, upon RRT initiation, is given by Iyq(0). After
6 months of follow-up, the distribution is given by
Iyq(0)Q(0,6); after 12 months: Iyq(0)Q(0,6)Q(6,12), and
so on. As an example, consider the year 2003. Incident
cases can occur any time between 01/01/2003 and 31/12/
2003, and if we assume that they occur uniformly over
that calendar time interval, then, on average, they will
occur at 30/06/2003. Then, we project I2003 from 06/30/
2003 to 31/12/2003 by I2003q(0)Q(0,6); from 31/12/2003 to
30/06/2004 by I2003q(0)Q(0,6)Q(6,12), . . . , and from
30/06/2005 to 31/12/2005 by:
I2003q(0)Q(0,6)Q(6,12)Q(12,18)Q(18,24)Q(24,30). Fig. 2. Renal replacement therapy initiation rates per 106 population:
Canada, 1981–96, and projections for 1997–2005 for non-diabetics (A)
This process is repeated for all projected incident co- and diabetics (B). Projected incidence rates were extrapolated from
Poisson regression models fitted to 1981–96 data.horts between 1997 and 2005. After summing the results
across I1997 to I2005, we have computed the contribution
to (year-end) 2005 prevalence from projected incident
ESRD cases. yields the contribution to year-end 2005 prevalence by
currently prevalent patients.Projecting follow-up of currently prevalent cases
Currently prevalent patients (i.e., those receiving RRT
RESULTSas of 31/12/1996) were categorized by RRT and length
of follow-up (6 month intervals). For example, patients Annual RRT initiation rates per 106 population in
with 3–9 months of follow-up were classified, for projec- Canada by diabetes status are displayed in Fig. 2. The
tion purposes, to have been followed for exactly 6 months. increase in incidence is projected to be highest for the
Those with 9–15 months of follow-up were considered $65 age group irrespective of diabetes status. Great in-
to be at month 12, and so on. Each prevalent cohort creases are projected for the 45–64 age group only among
vector was then projected out to 31/12/2005 by multiplying diabetics. Incidence rates are projected to remain stable
by the appropriate set of transition matrices. To illustrate, within in the #44 age group for both non-diabetics and
denote the vector of patients prevalent on 12/31/1996 diabetics.
with 12 prior months of follow-up by: p(12) 5 [p1(12), Year-end RRT-specific ESRD prevalence (number of
p2(12), p3(12), p4(12)]. We project this set of patients patients) during the 1981–2005 period is displayed in Fig.
from 31/12/1996 to 30/06/1997 by: p(12)Q(12,18); from 3A. It is projected that 32,952 patients will be receiving
30/06/1997 to 31/12/1997 by: p(12)Q(12,18)Q(18,24), and RRT in Canada as of Dec. 31, 2005: 13,754 on HD, 6501
so on, out to 31/12/2005. Repeating this procedure for on PD, and 12,697 with a functioning transplant. The
projected distribution by RRT for 2005 is virtually identi-p(0), p(6), p(12), p(18), . . . , and summing the results
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RRT initiation rates are currently much higher in other
developed countries such as the U.S., Germany and Ja-
pan [2–4] , with no obvious explanation why lower ESRD
incidence should be expected in Canada. Further in-
creases are projected for the U.S. [14].
The projection model presented is valid from a theo-
retical perspective [6]. Empirically, the method has proven
accurate, when evaluated via data splitting, as 1981–1987
data accurately projected 1988–1994 RRT prevalence
nationally [6], as did 1981–89 data for 1990–96 at the
provincial level [7]. Limitations of our projection model
have been discussed in detail previously [6, 7]. One note-
worthy liability is that, although we account for lack of
uniformity in transition probabilities over follow-up time,
we have assumed constancy over calendar time. Given
the supply of available donor organs has not nearly kept
pace with the demand, particularly in Canada, it is likely
that we over-estimate transplant probability for the
1997–2005 period. This would result in overestimation
of the number of transplanted patients, underestimation
of the number requiring dialysis. Another liability relates
to the fact that we have data on RRT utilization, not
true underlying ESRD incidence. Thus, the percentage
of patients initiating RRT among the population with
ESRD is not known, and is a quantity invaluable in
assessing the extent to which the observed increase in
RRT initiation rates could be expected to plateau. Note
that, although RRT initiation rates have demonstrated
no evidence of levelling off, even the supplementary
“constant incidence” model yielded large increases in
Fig. 3. End-stage renal disease prevalence (year-end number of regis- projected prevalence.tered patients): Canada, 1981–96, and projections for 1997–2005. The
We present a method for projecting ESRD prevalence.first set of prevalence projections are based on extrapolations of Poisson
models fitted to the 1981–96 data (A). The second set assumes that Such projections are useful in forecasting future facility,
incidence rates during 1997–2005 are constant and equal to the average equipment, manpower, and other resource requirements.rate experienced during 1994–96 (B). In both cases, a Markov model
Registry data, due to their volume, are invaluable forwas used to project patient follow-up.
research purposes, including future health care planning,
particularly when collected in the detail provided by
CORR.
cal to that observed in 1996: 42% HD; 20% PD; 39%
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